Geographical Variation in Patient Characteristics and Outcomes in Heart Failure with Mildly Reduced and Preserved Ejection Fraction
Authors:
Open Access
- 23 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 26 (8) , 1788-1803
Abstract
Aims: Compared to heart failure (HF) with reduced ejection fraction, HF with preserved ejection fraction (HFpEF), and HF with mildly reduced ejection fraction (HFmrEF) are increasing in prevalence, yet little is known about the geographic variation in patient characteristics, treatments and outcomes among these two HF phenotypes. The aim of this study was to investigate geographic differences in HFpEF and HFmrEF. Methods and results: We conducted an individual patient analysis of five clinical trials enrolling patients with HFpEF or HFmrEF from North America (NA), Latin America (LA), Western Europe (WE), Central/Eastern Europe and Russia (CEER), and Asia-Pacific (AP). We compared regions using descriptive statistics and multivariable regression models. Among the 19 959 patients included, 4066 (23.1%) had HFmrEF and 15 353 (76.9%) HFpEF. Regardless of HF phenotype, patients from WE were oldest, and those in CEER youngest. LA had the largest portion of females and NA most black patients. Obesity and diabetes were most prevalent in NA and hypertension and coronary heart disease most common in CEER. Self-reported health status varied strikingly and was the worst in NA and best in AP. Among patients with HFmrEF, rates of the primary composite endpoint (cardiovascular death or HF hospitalization) were: NA 12.56 per 100 patient-years (/100py), AP 11.67/100py, CEER 10.12/100py, LA 8.90/100py, and WE 8.43/100py, driven by differences in the rate of HF hospitalization. The corresponding values in HFpEF were 11.47/100py, 7.80/100py, 5.47/100py, 5.92/100py, and 7.80/100py, respectively. Conclusions: There is substantial geographic variation in patient characteristics, treatment and outcomes among patients with HFpEF and HFmrEF. These findings have implications for interpretation and generalizability of trial results, design and conduct of future trials, and optimization of care for these patients.Keywords
This publication has 38 references indexed in Scilit:
- Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass indexEuropean Journal of Heart Failure, 2021
- Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialEuropean Journal of Heart Failure, 2021
- Heart Failure Around the WorldEuropean Journal of Heart Failure, 2019
- Heart Failure with Reduced Ejection Fraction: Comparison of Patient Characteristics and Clinical Outcomes Within Asia and between Asia, Europe and the AmericasEuropean Journal of Heart Failure, 2018
- Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical TrialsJAMA Cardiology, 2018
- Geographic Differences in Heart Failure TrialsEuropean Journal of Heart Failure, 2015
- Global Variation in Clinical Profile, Management, and Post-Discharge Outcomes Among Patients Hospitalized For Worsening Chronic Heart Failure: Findings from the ASTRONAUT trialEuropean Journal of Heart Failure, 2015
- Heart Failure: Preventing Disease and Death WorldwideESC Heart Failure, 2014
- Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAmerican Heart Journal, 2011
- The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and DesignJournal of Cardiac Failure, 2005